Exploring new treatment targets for neurodegenerative diseases like ALS and FTD
Official title: Implementing a coupled system of integrative ML modeling and data validation for elucidating microglial therapeutic targets in neurodegenerative disease
Funded at Modulo Bio, INC. · NIH-10930134 · Data updated 2026-11-12
This study is looking into how diseases like ALS and FTD work, using smart computer tools to find new ways to help treat them, so that patients can eventually benefit from better therapies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Modulo Bio, INC. NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project start | September 15, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,428,644 |
| NIH project number | 5R44MH135465-02 |
| Project ID | NIH-10930134 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with ALS or FTD who are seeking new treatment options.
✕Less likely to help
Patients with neurodegenerative diseases other than ALS and FTD may not receive direct benefits from this research.
What this research studies
This research focuses on understanding the mechanisms behind neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) by utilizing advanced machine learning techniques. The team aims to create a comprehensive computational framework that integrates various datasets to identify potential therapeutic targets within the neuro-immune interface. By leveraging existing experimental data and innovative in vitro models, the project seeks to enhance our understanding of disease networks and improve target predictions for effective treatments. Patients may benefit from insights gained through this research that could lead to new therapeutic interventions.
Why it matters
Potential benefit: If successful, this research could lead to the identification of new therapeutic targets for treating ALS and FTD, potentially improving patient outcomes.
How similar studies have gone: While there have been various studies exploring neurodegenerative diseases, this approach of integrating machine learning with causal modeling is relatively novel and untested.
Where this research is happening
-
Modulo Bio, INC.
San Diego, United States Active
Researchers
- Principal investigator: Sachs, Karen — Modulo Bio, INC.
- Study coordinator: Sachs, Karen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.